Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Abeona Therapeutics (ABEO) over the last 12 years, with Sep 2025 value amounting to $2.5 million.

  • Abeona Therapeutics' Capital Expenditures rose 523.76% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 295.74%. This contributed to the annual value of $2.4 million for FY2024, which is 638.97% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Capital Expenditures of $2.5 million as of Q3 2025, which was down 13.13% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Capital Expenditures peaked at $3.2 million during Q4 2021, and registered a low of $2,000 during Q3 2022.
  • In the last 3 years, Abeona Therapeutics' Capital Expenditures had a median value of $606,000 in 2024 and averaged $872,636.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 9,742.42% in 2021, then tumbled by 99.50% in 2022.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Capital Expenditures stood at $3.2 million in 2021, then plummeted by 99.23% to $25,000 in 2022, then skyrocketed by 48.00% to $37,000 in 2023, then skyrocketed by 1,537.84% to $606,000 in 2024, then soared by 523.76% to $2.5 million in 2025.
  • Its Capital Expenditures was $2.5 million in Q3 2025, compared to $2.9 million in Q2 2025 and $1.4 million in Q1 2025.